One of the world-leading alternative protein producers, Calysta, has signaled its future intentions with the appointment of Dr Lori Giver, as Chief Science and Sustainability Officer.
Dr Giver first joined Calysta in 2013 as Vice President, Biological Engineering, before being appointed Vice President, Research and Development in 2019. In her new role, Lori will join the executive team and will play a key role in fulfilling Calysta’s ongoing commitment to the highest levels of sustainability.
Welcoming Lori into her new role, Calysta’s President, CEO and Co-Founder, Dr Alan Shaw, said: “This is a very important appointment for Calysta. Lori has played a pivotal role in our story so far and takes up this new position at a very exciting time for the business, with our first commercial-scale production facility to open in China later this year. Producing a sustainable protein that has no impact on biodiversity is a huge priority for us and this appointment underlines our determination to lower our footprint even further and fulfil our ongoing mission of making more from less.”
Like Alan Shaw, Dr Giver came to Calysta from Codexis, where she held a number of positions including Vice President of Systems Biology, Senior Director of Technology and Innovation, and Manager of Market Development. Lori completed post-doctoral studies with 2018 Nobel Prize for Chemistry winner Dr Frances Arnold. She is an author on numerous scientific publications and over 50 patents and patent applications.
On her appointment, Dr Giver said: “Calysta’s mission is to make more from less and I am passionate about fulfilling that ambition, which is why this new role is so exciting.
“By 2050, there will be two billion more people to feed on planet earth, but many of our existing food production techniques are unsustainable. The status quo cannot continue. We must strive to produce lower impact foods and feeds if we are to meet global demand. Calysta has a big role to play in addressing this and I will be working hard to improving our sustainability profile even further for current and future products from our proprietary fermentation platform,” added Dr Giver.
